|

Psychedelic Spotlight Interview with Rabbi Zac Kamenetz

BySarah Abelsohn



In this episode of the Psychedelic Spotlight podcast, we speak with Rabbi Zac Kamenetz, the Founder, and CEO of Shefa and the Co-Founder of the Jewish Psychedelic Summit.

In our conversation with Rabbi Zac, we discussed the forthcoming Jewish Psychedelic Summit, which kicks off on May 2, 2021, and which, in addition to himself, is being organized by Natalie Ginsberg from MAPS and Madison Margolin from DoubleBlind Magazine. The Summit is scheduled to feature an impressive list of guest speakers highlighted by Rick Doblin.

In addition to the Summit, we dive in and explore the connection between Judaism and psychedelics and how psychedelic therapies may one day bring relief to some of the millions of Jewish people across the globe suffering from the serious effects of trauma.

*To register for the Jewish Psychedelic Summit, go to: https://2021.jewishpsychedelicsummit.org

And to learn more about Rabbi Zac and the selfless contributions he is making to the Jewish community through his work, please visit https://shefaflow.org.

*Get the latest industry news around all things psychedelics by visiting our website, and be sure to subscribe to our newsletter to never miss a thing.

Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight

*This episode was recorded on April 20, 2021.

#Judiasm #Psychedelics #Summit #Trauma #PsychedelicTherapy

source

Similar Posts

  • MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]

    Listen, Videos

    Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
    On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.

    Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
    Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
    Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.

    On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….

    In this segment, we’ll discuss FOUR possible cases:
    Timestamps:
    0:00 – Intro
    4:17 – Worst Case
    7:48 – Probable Case
    9:57 – #WINNING CASE
    11:58 – APES TOGETHER STRONG CASE

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedNasdaq #MindMedstock

  • A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

    Listen, Videos

    A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

    Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic.
    This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%.
    For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b.
    Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more.
    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media!
    Instagram: @psychedelicinvestor
    James Twitter: @PSY_Invest
    Maria’s Twitter: @PSY_Holy

    Facebook: @thepsychedelicinvestor

    Email: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com

    Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Psilocybin #Psychedelics

  • MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]

    Listen, Videos

    So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.

    Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.

    Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
    most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.

    So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.

    Timestamps:
    0:00 – Intro
    1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
    6:05 – MindMed catalyst #1 – Atai’s IPO
    7:37 – PSIL ETF coming soon
    9:58 – Phase 2a results for MindMed’s Project LUCY
    11:38 – Project LUCY starting Phase2b in Q4 this year
    12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
    13:08 – Completion of Phase 1 LSD Neutralizer Study

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    Links to Clinical trials :

    https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
    https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

    https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

    https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedNasdaq #MindMedstock

  • MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)

    Listen, Videos

    Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

    1. MindMed’s Mission
    2. Their Talent acquisition
    3. The Progress of their different clinical trials
    4. The future

    Timestamps:
    0:00 – Intro
    1:59 – MindMed’s Mission
    4:36 – MMED’s talent acquisition
    7:24 – MindMed’s clinical trial progress
    10:48 – Psychiatry department : Project Lucy
    14:17 – Addiction department : Project Layla (18MC)
    18:33 – Pain department: Project Angie to treat pain card
    22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
    23:43 – MindMed (MMED / MNMD) and its future plans

    Enjoy!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD